About Be The Match BioTherapies

Your trusted partner empowering the discovery, development and delivery of next-generation therapies

Contact our team to start building your solution

Reliable solutions proven throughout the last 30 years to improve cell and gene therapies in any stage of development

Powered by the unrivaled experience, knowledge and global cell collection network of the National Marrow Donor Program®/Be The Match® and in close collaboration with our research partner, the CIBMTR® (Center for International Blood and Marrow Transplant Research®), we partner with global cell and gene therapy industry leaders to deliver high-quality, consistent and compliant therapies to patients in need.

We are the only solutions provider with customizable services to support any stage of the supply chain, prior to the point of patient identification and through patient outcomes data collection.

Whether your therapy is in research, pre-clinical or clinical studies, or commercially available, Be The Match BioTherapies® has the unparalleled industry expertise in designing valuable solutions to advance your therapy.

Cell sourcing solutions
immunogenetics-bioinformatics Created with Sketch. cellular-therapy-source-material Created with Sketch.
Supply chain solutions
collection-network-development-management Created with Sketch. quality-regulatory-services Created with Sketch. cell-delivery-logistics Created with Sketch. personalized-case-management Created with Sketch. matchsource-software Created with Sketch. outcomes-data-collection-analysis Created with Sketch.
Clinical research support
clinical-trial-design Created with Sketch. biorepository-sample-access Created with Sketch. observational-prospective-research Created with Sketch.

Our solutions power industry-leading commercialized therapies and build solid foundations for early-stage therapies advancing to market.

Be The Match BioTherapies provides critical services to support the development of life-saving cell and gene therapies including NK, CAR-T, engineered T-cell receptor, cord blood expansion, CTLs, and iPSCs to treat a variety of disorders, such as monogeneic and orphan diseases, liquid and solid tumors and primary immune deficiencies. These therapies range in development from late-stage clinical research to commercial delivery, and comply with FDA, EMA, TGA, HealthCanada and PMDA/MHLW regulations.

Be The Match BioTherapies is proud to support the development of life-saving therapies sponsored by more than 25 biopharmaceutical companies, including:

Our in-market portfolio of services includes:

  • Cell sourcing: Providing FDA and internationally compliant cellular starting material for multiple clinical trials sponsored by allogeneic cell biopharmaceutical companies and academic organizations. High-quality starting material is sourced from our registry of unpaid donors, and is provided through consistent, standardized processes that yield uniform volumes for further manufacture.
  • Apheresis collection network management: Collaborating with companies to qualify, onboard, support and manage custom networks of apheresis sites.
  • End-to-end cell therapy supply chain and logistics management: Providing end-to-end planning and oversight for the identification and contact of donors, collection and shipment of cells, and the logistics and delivery of the product to manufacturer, and the manufactured therapy to the patient.
  • U.S. and international apheresis site audits: Conducting quality system audits to ensure quality standards for FDA and international compliance for the collection of starting material for cell and gene therapies in clinical trials or commercially available through the Quality System Audit Program.
  • Clinical research support: Providing basic and clinical research support, primarily in transplant and therapies treating hematological malignancies. Our research partner, the CIBMTR® (Center for International Blood and Marrow Transplant Research®) has run 40 phase 2 and phase 3 trials through its NIH-funded clinical trial network and is currently supporting clinical development of an NK therapy for the treatment of AML and MDS, through the Blood and Marrow Transplant Clinical Trials Network.
  • Outcomes tracking: The CIBMTR is currently contracted to track long-term follow-up data for both approved CAR-T therapies, Kymriah and YESCARTA.